Vedana Therapeutics emerges from stealth with $46M Series A to develop anti-PACAP antibody therapies for migraine prevention. Led by the veterans who built the CGRP drug class, the startup targets a neuropeptide pathway that could help the 50%+ of patients who don't respond to current treatments.
TearSolutions' Lacripep, a synthetic peptide derived from human tear protein, has won both Orphan Drug and Fast Track designations from the FDA for neurotrophic keratitis. Phase 2 dosing has begun.
TearSolutions' synthetic peptide Lacripep secured FDA Orphan Drug and Fast Track designations for neurotrophic keratitis, a rare degenerative corneal disease. A Phase 2 trial in 54 patients is now underway.
Cenna Biosciences wins FDA clearance for a first-in-class peptide that stops amyloid production rather than clearing plaques — a fundamentally different approach to Alzheimer's disease.
